Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 5/20 | 0.39 |
| ▸ | CA12 | O43570 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | CCR9 | P51686 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5766292 | 0.86 | CA12 (0.41) | CA9CA12CA1CA2ALDH1A1 | |
| SCHEMBL6101383 | 0.85 | CA1 (0.40) | CA9CA12CA1CA2ALDH1A1 | |
| SCHEMBL4150996 | 0.85 | CYP1A2 (0.51) | CA9CA12CA1CA2ALDH1A1 | |
| SCHEMBL6102631 | 0.85 | CHRM5 (0.41) | CA9CA12CA1CA2CA7 | |
| SCHEMBL6099606 | 0.85 | GAA (0.41) | CA9CA12CA1CA2MEN1 | |
| SCHEMBL6101670 | 0.83 | KDM4E (0.42) | CA9CA12CA1CA2ALDH1A1 | |
| SCHEMBL5793964 | 0.82 | FAAH (0.49) | CA9CA12CA1CA2ALDH1A1 | |
| SCHEMBL5768146 | 0.82 | KDM4E (0.52) | CYP1B1ALDH1A1KDM4EMEN1HPGD | |
| SCHEMBL6100789 | 0.81 | CMA1 (0.53) | ALDH1A1KDM4EMEN1KMT2APKM | |
| SCHEMBL5767183 | 0.81 | KMT2A (0.46) | CA9CA12CA1CA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060211724-A1 | Hiv integrase inhibitors | VERSCHUEREN GASTON W | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211724-A1 | Hiv integrase inhibitors | SULT1A1, SULT2A1, SULT1E1 | CYP1B1 23/4885CA9 1900/4885CA12 4585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.